Funding Round

Ridge Bio Secures $25M Seed for AI-Enabled Drug Design

StartupHub.ai Staff

By StartupHub.ai Staff, reviewed by Daniel Singer, Editor

1 min read

Ridge Bio Secures $25M Seed for AI-Enabled Drug Design

Ridge Biotechnologies, a Palo Alto-based startup, emerged from stealth with $25 million in oversubscribed seed financing. Sutter Hill Ventures incubated Ridge Bio and led the round. Overlap Holdings also participated in this funding.

Ridge Bio pioneers enzyme and targeted drug design, powering the next wave of precision medicine. The company leverages proprietary machine learning models and high-throughput, cell-free experimentation. This advanced approach enables a new class of precisely engineered enzyme-based therapeutics, central to AI-enabled drug design.

Advancing Precision Therapeutics with AI

The Ridge Bio platform applies its technology across various applications, including antibody-drug conjugates (ADCs) and in vivo CAR-T therapies. Its initial offerings include NativeLink enzymes and ProTrigger linkers. NativeLink enzymes modify therapeutic proteins site-specifically, while ProTrigger linkers are AI-designed prodrug systems for targeted payload release.

Ridge Bio also announced a collaboration with a leading ADC-focused biotech. This partnership utilizes ProTrigger and NativeLink product lines.

Weston Kightlinger, PhD, co-founded and leads Ridge Bio as CEO. He previously co-founded SwiftScale Biologics, acquired by Resilience. The company's advisory board includes Nobel Laureate Carolyn Bertozzi, PhD, and Stanford Professor Mike Jewett, PhD.

Sources

Get the free daily brief every morning

Every morning the day's AI news, new AI startups and new funding rounds. Free and takes a few minutes to read, unsubscribe at any time.

Join 64,000 other subscribers.

TopicsAIBiotechCarolyn BertozziDrug DesignFundingRidge BioSutter Hill VenturesWeston Kightlinger

StartupHub.ai Staff

Written by

StartupHub.ai StaffEditorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.

Daniel Singer

Reviewed by

Daniel Singer is an AI expert who has been writing about, covering and building AI technology since 2018.

Test your Agent Readiness now

Paste your website. How well ChatGPT, Claude and the other agents can read and use a site, in about a minute.

Watch

The videos behind the news, one flip at a time

The feed mixes the videos from our articles with startup demos and you flip through them like TV channels for free with no signup.